Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | CHAARTED: ADT + docetaxel for prostate cancer

Anis Hamid • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Abiraterone Apalutamide Docetaxel Enzalutamide
CHAARTED

Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, discusses a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (HSPC), from the CHAARTED study (NCT00309985). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Anis Hamid

1:30
How far away are we from implementing CTC-based approaches in prostate cancer?
Anis Hamid • 6 Jun 2022
1:26
Remaining questions on PSMA PET imaging in prostate cancer
Anis Hamid • 6 Jun 2022
3:25
Elucidating biomarkers of prognosis of 177Lu-PSMA-617-based therapy
Anis Hamid • 6 Jun 2022
1:17
PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer
Anis Hamid • 6 Jun 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals